PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
February 8, 2026Antibiotics0 citationsOpen Access

Acquisition Origin Matters: Clinical, Microbiological and Immunological Characteristics and Treatment Effects in Community- vs. Hospital-Acquired Septic Shock

ICIrene ColorettiMTMartina TosiIGIlenia Gatto

Key Points

  • This study aims to explore the differences in clinical characteristics, immunological responses, and treatment outcomes between community-acquired and hospital-acquired septic shock.
  • Retrospective cohort analysis of 726 adults with septic shock admitted to two ICUs
  • Patients classified into community-acquired and hospital-acquired septic shock based on infection origin
  • Clinical, microbiological, and immunological data were collected and analyzed
  • Multivariable Cox regression models identified predictors and treatment effects on ICU mortality
  • Patients with community-acquired septic shock had higher severity scores but lower ICU and in-hospital mortality than those with hospital-acquired shock
  • Hospital-acquired patients showed a higher rate of multidrug-resistant organisms and more comorbidities
  • Community-acquired survivors experienced increasing lymphocyte counts over time, while hospital-acquired survivors showed recovery in T helper cells
  • No significant mortality benefit was found from standard treatments like antibiotics or steroids.

Abstract

Background: Septic shock is a leading cause of mortality worldwide, with community-acquired (CA) and hospital-acquired (HA) infections representing distinct clinical entities. The differences in clinical characteristics, immune response profiles, and effects of sepsis treatments between CA and HA septic shock have not been fully elucidated. Methods: This retrospective cohort study included 726 adults with septic shock who were admitted to two ICUs at Modena University Hospital between January 2006 and September 2024. Patients were classified as having CA or HA septic shock based on the origin of the infection. Clinical, microbiological, and immunological data, treatments, and outcomes were analysed. Immune cell dynamics were assessed during the first week after the onset of the shock. Multivariable Cox regression models were used to identify predictors and the effects of treatment on ICU mortality. Results: Among 344 patients with CA and 382 with HA septic shock, those with CA had higher severity scores but lower ICU and in-hospital mortality. Patients with HA exhibited a higher prevalence of multidrug-resistant organisms and more comorbidities. Immunologically, CA survivors showed increasing lymphocyte counts over time, whereas HA survivors mainly demonstrated recovery in T helper cells. Therapeutic strategies were similar between groups; however, continuous renal replacement therapy was more frequent in patients with HA. Neither appropriate empiric antibiotics nor steroids or immunoglobulin therapy independently improved mortality in the multivariate analyses. Conclusions: CA and HA septic shock differ significantly in terms of clinical severity, microbiological aetiology, immune recovery patterns, and outcomes. The lack of mortality benefit from standard treatments highlights the need for personalised management strategies that integrate clinical, immunological, and microbiological data to optimise care in septic shock subpopulations.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Coloretti et al. (2026) studied this question.

synapsesocial.com/papers/698827e20fc35cd7a8846eaehttps://doi.org/10.3390/antibiotics15020169
Ask AI
Helpful
Bookmark
Share
View Full Paper

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Infectious Foci, Comorbidities and Its Influence on the Outcomes of Septic Critically Ill Patients2024 · 4 citations
  2. 2P-1528. Investigating Patient and Microbiological Factors to Unravel the Path to Septic Shock2026
  3. 3Racial and ethnic differences in COVID-19-associated septic shock2025
  4. 4A twenty-year retrospective analysis on sepsis and septic shock incidence and mortality2026
  5. 5Characteristics and Clinical Outcomes of Septic Aki Compared to Non-Septic Aki: A Hospital Based Prospective Cohort Study2025